MODERNA INC (MRNA)
Sector: Health Care
2026 Annual Meeting Analysis
MODERNA INC · Meeting: May 6, 2026
Directors FOR
1
Directors AGAINST
1
Say on Pay
AGAINST
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Dr. Horning has served since 2020, giving her full overlap with Moderna's severe 3-year stock underperformance: MRNA's 3-year return is -66.9% versus the compensation peer group median of +34.8%, a gap of -101.7 percentage points that far exceeds the 20-percentage-point trigger threshold for companies with negative absolute returns; the 5-year gap of -99.3pp versus the peer median of +37.2% also exceeds the threshold, confirming this is sustained underperformance rather than a temporary trough, so no 5-year mitigant applies.
For Analysis
Mr. Hussain joined the board in 2024, which is within the 24-month exemption window, so he is not held accountable for the prior underperformance period and receives a FOR vote.
Of the two Class II nominees, Abbas Hussain is exempt from the TSR trigger because he joined in 2024 (within 24 months of this meeting). Sandra Horning, who has served since 2020, has full overlap with Moderna's severe underperformance: the stock has lost roughly two-thirds of its value over three years while the compensation peer group median rose about 35%, a gap of over 100 percentage points well beyond the 20-point trigger for companies with negative absolute returns, and the 5-year data confirms sustained rather than transient underperformance.
Say on Pay
✗ AGAINSTCEO
Stéphane Bancel
Total Comp
$19,932,217
Prior Support
77%%
The prior say-on-pay vote cleared the 70% threshold (77% support in 2025), so no automatic No vote is triggered on that basis, and the pay mix is strong — over 90% of CEO compensation is at-risk variable pay including performance stock awards and stock options, which satisfies the pay mix test. However, the pay-for-performance alignment check fails: the annual cash bonus was paid at 170% of target in a year when the company's 3-year stock return is -66.9% versus the compensation peer group median of +34.8%, a gap of over 100 percentage points — the incentive pay was clearly above benchmark levels while shareholders experienced severe losses relative to peers over the same period. The cash bonus scorecard rewarded cost-cutting metrics heavily while the company missed its revenue targets, and the committee's discretion to drive a 170% payout in this environment is inconsistent with the principle that above-benchmark variable pay should only be justified when shareholder returns are in line with or above sector peers.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$5,140,389
Non-Audit Fees
$214,987
Non-audit fees (tax fees of $150,000 plus all other fees of $64,987, totaling $214,987) represent approximately 4.2% of audit fees of $5,140,389, well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot be applied, and there are no disclosed material restatements; Ernst & Young is a Big 4 firm appropriate for Moderna's size and complexity.
Overall Assessment
This ballot presents four proposals at Moderna's 2026 annual meeting. The most significant concern is director accountability for sustained and severe stock underperformance — MRNA has lost roughly two-thirds of its value over three years while biotech peers (XBI — SPDR S&P Biotech ETF) rose 68% and the company's own compensation peer group median rose 35%, triggering an AGAINST vote for long-tenured director Sandra Horning; the say-on-pay vote also warrants an AGAINST because the board paid the CEO and executives a 170% bonus despite missing revenue targets and devastating shareholder returns relative to peers, while the auditor ratification passes cleanly with non-audit fees at only 4% of audit fees.
Compensation Peer Group
17 companies disclosed in 2026 proxy filing